Kymriah 1.2 x 106 – 6 x 108 cells dispersion for infusion
*Company:
Novartis Ireland LimitedStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
- SPC
- Patient Leaflets
- Ed Material - HCP
- Ed Material - Patient
- Additional Comms
- Licence Info
- Doc History
(Click to Download) DHPC - Risk of secondary malignancy of T-cell origin in CD19- or BCMA-directed CAR T-cell therapies
Direct Healthcare Professional Communication (DHPC)